IRWDIronwood Pharmaceuticals
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ:IRWD) is a dynamic player in the pharmaceutical field, focusing on the discovery, development, and commercialization of innovative medicines designed to address significant unmet needs. With a keen eye on gastrointestinal and cardiovascular diseases among other therapeutic areas, Ironwood is dedicated to pushing the boundaries of science to improve patient outcomes. A core project is the marketing and further development of Linzess®, a treatment for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), reflecting the company's commitment to tackling prevalent yet challenging conditions. Central to its mission, Ironwood aims to leverage its deep expertise in pharmacology and innovative patient-care approaches to expand its portfolio, driving growth and delivering value to patients and shareholders alike.
What is IRWD known for?
Snapshot
Public US
Ownership
1998
Year founded
335
Employees
Massachusetts, United States
Head office
1 of 1
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of Ironwood Pharmaceuticals
- Drug Discovery and Development: They identify and develop potential drug candidates through scientific research and preclinical testing, targeting specific therapeutic areas.
- Clinical Trials: Ironwood conducts clinical trials in humans to evaluate the safety and efficacy of their drug candidates in various stages of development.
- Regulatory Affairs: They work with regulatory agencies like the FDA to obtain marketing approval for their drugs, allowing them to be prescribed to patients.
- Partnerships and Collaborations: They collaborate with other pharmaceutical companies to leverage expertise and resources for broader development and commercialization of their drugs or in-license drugs from other companies for further development and potential commercialization.
- Manufacturing and Supply Chain: While not directly involved in large-scale manufacturing, they may partner with other companies to ensure the quality and supply of their drugs if they reach the market.
- Commercialization (limited): In some cases, Ironwood may participate in limited commercialization activities for their approved drugs, such as sales and marketing efforts alongside their partner companies. However, their primary focus remains on drug discovery, development, and obtaining regulatory approvals.
Ironwood Pharmaceuticals executive team
- Mr. Thomas A. McCourtCEO & Director
- Mr. John MinardoSenior VP, Chief Legal Officer & Secretary
- Dr. Michael Shetzline M.D., Ph.D.Chief Medical Officer, Senior VP and Head of Research & Drug Development
- Mr. Gregory MartiniSenior VP, CFO & Investor Relations
- Mr. Ronald SilverSenior VP, Corporate Controller & Principal Accounting Officer
- Dr. Rosario Lobrutto M.B.A., M.S., Ph.D.VP & Global Head of Technical Operations
- Ms. Tammi GaskinsSenior Vice President & Chief Commercial Officer.
- Mr. Jeff RubertiChief Strategy Officer